Literature DB >> 3129957

Propofol in total intravenous anaesthesia without nitrous oxide.

P A Steegers1, P A Foster.   

Abstract

Propofol and methohexitone were evaluated as hypnotics in a total intravenous anaesthesia technique without nitrous oxide in 50 patients of ASA grade 1 or 2. Analgesia was provided by a constant alfentanil infusion and the depth of anaesthesia was controlled by varying the infusion rate of propofol or methohexitone. Induction and intubation responses were smooth and moderate in the propofol group and side effects were few. Control of depth of anaesthesia, blood pressure and pulse rate was relatively easy in this group but more difficult and sometimes inadequate in the methohexitone group, in which side effects were more frequent. The mean infusion rate for propofol was 0.12 mg/kg/minute, similar to those found in studies using nitrous oxide without an opioid. Recovery times were short in both groups but those in the propofol group tended to be shorter. Postoperatively 96% of the propofol patients were clear-headed within 20 minutes, in contrast to only 48% in the methohexitone group. We conclude that propofol together with alfentanil, both given by a bolus plus infusion technique, provide controllable and satisfactory total intravenous anaesthesia without recourse to nitrous oxide or other inhalational agents. Methohexitone was not as satisfactory as propofol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129957     DOI: 10.1111/j.1365-2044.1988.tb09085.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  2 in total

1.  Total intravenous anaesthesia with propofol, alfentanil, and oxygen-air: three different dosage schemes.

Authors:  L van Leeuwen; W W Zuurmond; L Deen; H J Helmers
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

2.  Methohexital in total intravenous anesthesia during intraoperative neurophysiological monitoring.

Authors:  Tod B Sloan; Jacqueline Vasquez; Evalina Burger
Journal:  J Clin Monit Comput       Date:  2013-06-29       Impact factor: 2.502

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.